IT1250749B - Composti eterociclici ad attivita' a ii antagonista - Google Patents

Composti eterociclici ad attivita' a ii antagonista

Info

Publication number
IT1250749B
IT1250749B ITMI912182A ITMI912182A IT1250749B IT 1250749 B IT1250749 B IT 1250749B IT MI912182 A ITMI912182 A IT MI912182A IT MI912182 A ITMI912182 A IT MI912182A IT 1250749 B IT1250749 B IT 1250749B
Authority
IT
Italy
Prior art keywords
antagonist
alkyl
heterocyclic compounds
optionally substituted
compounds activated
Prior art date
Application number
ITMI912182A
Other languages
English (en)
Inventor
Aldo Salimbeni
Davide Poma
Elso Manghisi
Carlo Scolastico
Original Assignee
Luso Farmaco Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Luso Farmaco Inst filed Critical Luso Farmaco Inst
Publication of ITMI912182A0 publication Critical patent/ITMI912182A0/it
Priority to ITMI912182A priority Critical patent/IT1250749B/it
Priority to PCT/EP1992/001753 priority patent/WO1993003018A1/en
Priority to RO94-00144A priority patent/RO113987B1/ro
Priority to JP5503271A priority patent/JPH06509349A/ja
Priority to AU23873/92A priority patent/AU668357B2/en
Priority to RU9494015173A priority patent/RU2098411C1/ru
Priority to CA002114621A priority patent/CA2114621A1/en
Priority to HU9400267A priority patent/HUT67666A/hu
Priority to US08/193,025 priority patent/US5565464A/en
Priority to PL92302346A priority patent/PL174986B1/pl
Priority to SK106-94A priority patent/SK10694A3/sk
Priority to FI940355A priority patent/FI940355A7/fi
Priority to EP92916506A priority patent/EP0641329A1/en
Priority to CZ94169A priority patent/CZ16994A3/cs
Publication of ITMI912182A1 publication Critical patent/ITMI912182A1/it
Priority to NO940321A priority patent/NO940321L/no
Priority to BG98430A priority patent/BG61692B1/bg
Application granted granted Critical
Publication of IT1250749B publication Critical patent/IT1250749B/it

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • C07D239/36—One oxygen atom as doubly bound oxygen atom or as unsubstituted hydroxy radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Composti di formula I (FORMULA I) con R = C1-C4 alchile; R1 = H, C1-C4 alchile, arile o aralchile eventualmente sostituiti; R2 = H, C1-C4 alchile, OH, NH2 o arile eventualmente sostituito; R3 = alogeno; X = CO, C-OR1 o C-CH2OR5, con R5 = H, C1-C4 alchile o aralchile eventualmente sostituito; e Z = carbossile, alcossicarbonile o tetrazol-5-ile; sono dotati di proprietà A II antagonisti e si prestano per la terapia di patologie cardiache e vascolari.
ITMI912182A 1991-08-02 1991-08-02 Composti eterociclici ad attivita' a ii antagonista IT1250749B (it)

Priority Applications (16)

Application Number Priority Date Filing Date Title
ITMI912182A IT1250749B (it) 1991-08-02 1991-08-02 Composti eterociclici ad attivita' a ii antagonista
US08/193,025 US5565464A (en) 1991-08-02 1992-08-03 Compounds having angiotensine II antagonistic activity
SK106-94A SK10694A3 (en) 1991-08-02 1992-08-03 Compounds having angiotensine ii antagonistic activity
JP5503271A JPH06509349A (ja) 1991-08-02 1992-08-03 アンジオテンシン２拮抗活性を有する化合物
AU23873/92A AU668357B2 (en) 1991-08-02 1992-08-03 Compounds having angiotensine II antagonistic activity
RU9494015173A RU2098411C1 (ru) 1991-08-02 1992-08-03 Производные пиримидина, способ их получения, фармацевтическая композиция на их основе
CA002114621A CA2114621A1 (en) 1991-08-02 1992-08-03 Compounds having angiotensine ii antagonistic activity
HU9400267A HUT67666A (en) 1991-08-02 1992-08-03 Biphenylil methyl pyrimidine derivatives having angiotensine ii antagonistic activity and pharmaceutical compositions containing them
PCT/EP1992/001753 WO1993003018A1 (en) 1991-08-02 1992-08-03 Compounds having angiotensine ii antagonistic activity
PL92302346A PL174986B1 (pl) 1991-08-02 1992-08-03 Sposób wytwarzania związków o działaniu antagonistycznym względem angiotensyny II
RO94-00144A RO113987B1 (ro) 1991-08-02 1992-08-03 Derivati de pirimidin-6-ona
FI940355A FI940355A7 (fi) 1991-08-02 1992-08-03 Yhdisteet, joilla on angiotensiini II:ta vastustava vaikutus
EP92916506A EP0641329A1 (en) 1991-08-02 1992-08-03 Compounds having angiotensine ii antagonistic activity
CZ94169A CZ16994A3 (en) 1991-08-02 1992-08-03 Heterocyclic compounds and pharmaceutical preparations in which they are comprised
NO940321A NO940321L (no) 1991-08-02 1994-01-31 Forbindelser med angiotensin II - antagonistisk aktivitet
BG98430A BG61692B1 (bg) 1991-08-02 1994-01-31 Съединения с ангиотензин ii антагонистична активност

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ITMI912182A IT1250749B (it) 1991-08-02 1991-08-02 Composti eterociclici ad attivita' a ii antagonista

Publications (3)

Publication Number Publication Date
ITMI912182A0 ITMI912182A0 (it) 1991-08-02
ITMI912182A1 ITMI912182A1 (it) 1993-02-02
IT1250749B true IT1250749B (it) 1995-04-21

Family

ID=11360517

Family Applications (1)

Application Number Title Priority Date Filing Date
ITMI912182A IT1250749B (it) 1991-08-02 1991-08-02 Composti eterociclici ad attivita' a ii antagonista

Country Status (14)

Country Link
US (1) US5565464A (it)
EP (1) EP0641329A1 (it)
JP (1) JPH06509349A (it)
AU (1) AU668357B2 (it)
BG (1) BG61692B1 (it)
CA (1) CA2114621A1 (it)
CZ (1) CZ16994A3 (it)
FI (1) FI940355A7 (it)
HU (1) HUT67666A (it)
IT (1) IT1250749B (it)
PL (1) PL174986B1 (it)
RO (1) RO113987B1 (it)
SK (1) SK10694A3 (it)
WO (1) WO1993003018A1 (it)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100300566B1 (ko) * 1994-09-17 2001-11-22 조생현 피리미디논유도체와그의제조방법및용도
IT1283620B1 (it) * 1996-04-19 1998-04-22 Luso Farmaco Inst "pirimidin-4-oni n-3 sostituiti ad attivita' aii antagonista"
CA2176058C (en) * 1996-05-08 1999-03-02 William Nicholas Goodway Three-dimensional seismic acquisition
DK1027328T3 (da) * 1997-10-31 2006-11-13 Aventis Pharma Ltd Substituerede anilider
SE9903028D0 (sv) 1999-08-27 1999-08-27 Astra Ab New use
AU2004270161A1 (en) * 2003-08-28 2005-03-17 Nicox S.A. Nitrosated and nitrosylated cardiovascular compounds, compositions and methods of use
WO2006093864A1 (en) * 2005-02-28 2006-09-08 Nitromed, Inc. Cardiovascular compounds comprising nitric oxide enhancing groups, compositions and methods of use
US20090215838A1 (en) * 2005-03-09 2009-08-27 Nitromed, Inc. Organic nitric oxide enhancing salts of angiotensin ii antagonists, compositions and methods of use
EA015890B1 (ru) * 2005-06-14 2011-12-30 Тайджен Байотекнолоджи Ко. Лтд. Производные пиримидина
US8193206B2 (en) 2005-06-14 2012-06-05 Taigen Biotechnology Co., Ltd. Pyrimidine compounds
US7803940B2 (en) * 2006-11-24 2010-09-28 Takeda Pharmaceutical Company Limited Heteromonocyclic compound or a salt thereof having strong antihypertensive action, insulin sensitizing activity and the like production thereof and use thereof for prophylaxis or treatment of cardiovascular diseases, metabolic diseases and/or central nervous system diseases
EA200970510A1 (ru) * 2006-11-24 2009-12-30 Такеда Фармасьютикал Компани Лимитед Гетеромоноциклическое соединение и его применение
WO2008151257A2 (en) 2007-06-04 2008-12-11 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
ES2627848T3 (es) 2008-06-04 2017-07-31 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
ES2624828T3 (es) 2008-07-16 2017-07-17 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros
ES2433225T3 (es) 2009-01-30 2013-12-10 Takeda Pharmaceutical Company Limited Compuesto con anillos condensados y uso del mismo
EP2420501A4 (en) 2009-04-17 2012-08-29 Kowa Co NEW COMPOUNDS WITH 3-HETEROARYLPYRIMIDIN-4- (3H) -ONE STRUCTURE AND PHARMACEUTICAL PREPARATION THEREWITH
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
US9708367B2 (en) 2013-03-15 2017-07-18 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase and their uses
EP2968439A2 (en) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
PL3004138T3 (pl) 2013-06-05 2024-07-29 Bausch Health Ireland Limited Ultra-oczyszczeni agoniści peptydowi cyklazy guanylanowej C, sposób ich uzyskiwania i ich zastosowanie
KR102131022B1 (ko) * 2018-07-12 2020-07-07 보령제약 주식회사 피리미디논 유도체 화합물 및 이의 용도

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0424317A3 (en) * 1989-10-19 1991-09-25 Ciba-Geigy Ag Pyrimidines
EP0435827A3 (en) * 1989-12-28 1991-11-13 Ciba-Geigy Ag Diaza compounds
US5166206A (en) * 1990-03-30 1992-11-24 Merck & Co., Inc. Substituted pyrimidines, pyrimidinones and pyridopyrimidines
WO1991015209A1 (en) * 1990-03-30 1991-10-17 Merck & Co., Inc. Substituted pyrimidines, pyrimidinones and pyridopyrimidines
IE912114A1 (en) * 1990-07-02 1992-01-15 Union Pharma Scient Appl Novel pyrimidine derivatives which are angiotensin ii¹receptor antagonists, their methods of preparation and¹pharmaceutical compositions in which they are present

Also Published As

Publication number Publication date
ITMI912182A0 (it) 1991-08-02
RO113987B1 (ro) 1998-12-30
FI940355A0 (fi) 1994-01-25
HUT67666A (en) 1995-04-28
AU2387392A (en) 1993-03-02
SK10694A3 (en) 1994-12-07
BG98430A (bg) 1994-09-30
JPH06509349A (ja) 1994-10-20
EP0641329A1 (en) 1995-03-08
BG61692B1 (bg) 1998-03-31
FI940355L (fi) 1994-01-25
HU9400267D0 (en) 1994-05-30
WO1993003018A1 (en) 1993-02-18
FI940355A7 (fi) 1994-01-25
PL174986B1 (pl) 1998-10-30
AU668357B2 (en) 1996-05-02
CZ16994A3 (en) 1994-06-15
ITMI912182A1 (it) 1993-02-02
CA2114621A1 (en) 1993-02-18
US5565464A (en) 1996-10-15

Similar Documents

Publication Publication Date Title
DE69425162D1 (de) 4,5-diaryloxazol-derivate
MY108885A (en) Heterocyclic-cyclic amine derivatives.
TR200201205T2 (tr) N-ikame edilmiş karbamoiloksialkil-azolyum türevleri.
DE69232022D1 (de) Naphthyridinderivate als Angiotensin-II-Antagonist-Inhibitoren
BG106586A (en) Pyrazolopyramidines as therapeutic agents
AU2002246728A1 (en) Carboline derivatives
DE69618231D1 (de) TETRAHYDROIMIDAZOPYRIDOINDOLDIONE ALS cGMP SPEZIFISCHE PDE HEMMER
ATE109481T1 (de) Diazinderivate als angiotensin ii rezeptor antagonisten.
ATE346067T1 (de) Carbolinderivate
ATE332302T1 (de) Alkylierte imidazopyridinderivate
DE69823493D1 (de) Tetrahydropyridoverbindungen
EA200300392A1 (ru) Производные пиперазина с мостиковой связью
TW350838B (en) Quinoline derivatives
DE69330601D1 (de) Serotoninergische ergolin derivate
ATE119878T1 (de) Hydrazone.
FI935799A0 (fi) Arylsubstituerade heterocykliska foereningar
DE59108566D1 (de) Heteroarylmethylbenzole-Aromatasehemmer
ZA877454B (en) Therapeutic agent for the treatment of peptic ulcer disease
MY133140A (en) N-substituted azabicycloheptane derivatives, their preparation and use
NO20021310L (no) Aminderivater
DE69403896D1 (de) 4-amino-2-(hetero)aryl-butanamide verwenbar als 5-ht1a-antagonisten
JO1648B1 (en) Nitrogen compounds

Legal Events

Date Code Title Description
0001 Granted
TA Fee payment date (situation as of event date), data collected since 19931001

Effective date: 19960826